FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of December 2020
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Director/PDMR Shareholding
17 December 2020 16:00 GMT
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below. Two ADSs are equivalent to one Ordinary Share.
| PDMR | Position | Nature of the transaction | Quantity | Price |
| Michel Demaré | Non-Executive Director | Purchase of Ordinary Shares | 1,300 | GB£76.80 |
| Euan Ashley | Non-Executive Director | Purchase of ADSs | 700 | US$51.52 |
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
1 | Details of the person discharging managerial responsibilities / person closely associated |
a) | Name | Michel Demaré |
2 | Reason for the notification |
a) | Position/status | Non-Executive Director |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) | Name | AstraZeneca PLC |
b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
b) | Nature of the transaction | Purchase of AstraZeneca PLC Ordinary Shares |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| GB£76.80 | 1,300 |
d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction |
e) | Date of the transaction | 16 December 2020 |
f) | Place of the transaction | XLON |
1 | Details of the person discharging managerial responsibilities / person closely associated |
a) | Name | Euan Ashley |
2 | Reason for the notification |
a) | Position/status | Non-Executive Director |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) | Name | AstraZeneca PLC |
b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) | Description of the financial instrument, type of instrument Identification code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 |
b) | Nature of the transaction | Purchase of AstraZeneca PLC American Depositary Shares |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| US$51.52 | 700 |
d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction |
e) | Date of the transaction | 16 December 2020 |
f) | Place of the transaction | XNAS |
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: 17 December 2020
| | By: /s/ Adrian Kemp |
| | Name: Adrian Kemp |
| | Title: Company Secretary |
